Regulus Therapeutics

Type: Company
Name: Regulus Therapeutics
First reported 3 hours ago - Updated 3 hours ago - 2 reports

Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call

SOURCE Regulus Therapeutics Inc.LA JOLLA, Calif.Regulus will host a conference call and webcast on Wednesday, August 6, 2014About RegulusRegulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative ... [Published 14 WFIE - 3 hours ago]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Regulus Therapeutics Director Sells $11,135 in Stock (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 1,700 shares of the stock on the open market in a transaction dated Friday, July 25th. The stock was sold at an average price of $6.55, for a total transaction of $11,135.00. The ... [Published American Banking News - Jul 26 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Regulus Gains Orphan Drug Designation for microRNA Treatment

A recent press release  by the company Regulus Therapeutics highlights their newest orphan drug RG-012 – a microRNA treatment designed to help patients with Alport Syndrome, a life-threatening genetic kidney disease that impacts the body’s ability to ... [Published Terrapinn - Jul 24 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 5 reports

Regulus gets FDA orphan drug status for RG-012 to treat Alport Syndrome

US-based biopharmaceutical firm Regulus Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for RG-012, a single stranded, chemically modified oligonucleotide. ... [Published PBR - News - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 2 reports

Regulus Therapeutics Director Isis Pharmaceuticals Inc Sells 5,000 Shares (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc unloaded 5,000 shares of the stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $6.58, for a total value of $32,900.00. The transaction was ... [Published American Banking News - Jul 21 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Healthcare Review: Herbalife, Regulus Therapeutics, Supreme Pharmaceuticals, Rexahn Pharmaceuticals, Gentiva Health Services

U.S. stocks rebounded and European markets recovered a bit on Friday but the euro dipped below $1.35 for first time since February after a Malaysian airliner was downed in eastern Ukraine and Israel stepped up a ground assault in Gaza.German Bund yields ... [Published BioMedReports - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Orphan Drug status for Regulus kidney disease therapeutic candidate

11:19 ET | About: Regulus Therapeutics (RGLS)The FDA designates Regulus Therapeutics' (RGLS +3%) miR-21 inhibitor RG-012 an Orphan Drug for the treatment of Alport syndrome. miR-21 is a 22-mer non-coding RNA that is up-regulated in fibrotic kidney disease. ... [Published Seeking Alpha - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 17 2014 - 1 reports

Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx

CARLSBAD, Calif.ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this ... [Published ADVFN UK - Jul 16 2014]
First reported Jul 12 2014 - Updated Jul 12 2014 - 1 reports

Regulus Therapeutics Director 1,750 Shares of Stock (RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc 1,750 shares of Regulus Therapeutics stock on the open market in a transaction dated Friday, July 11th. The was disclosed in a filing with the SEC, which is available at this link.Shares ... [Published American Banking News - Jul 12 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

"Regulus Therapeutics Inc. - Product Pipeline Review - 2014" Is Now Available at Fast Market Research

Boston, MA -- (SBWIRE) -- 07/03/2014 -- Global Markets Direct's, 'Regulus Therapeutics Inc. - Product Pipeline Review - 2014', provides an overview of the Regulus Therapeutics Inc.'s pharmaceutical research and development focus. ... [Published Good Day Sacramento - Jul 03 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 2 reports

Regulus Announces Patent Grant from U.S. Patent -2-

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with financial estimates ... [Published Scottrade - Jun 25 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 2 reports

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx

/PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy ... [Published CEOWorld Magazine - Jun 24 2014]

Quotes

"Sorrento Therapeutics Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report" Now Available at Fast Market Research
...like microRNA therapeutics for rare and orphan diseases such as Alport syndrome," said Paul Grint, M D , Chief Medical Officer of Regulus.  "Alport syndrome is a life threatening disease and patients have very limited treatment options because there is currently no approved therapy.  We believe that RG-012 represents an opportunity to make a significant impact in the lives of patients with Alport syndrome and we look forward to advancing this program into the clinic." In the near term, Regulus expects to initiate a natural history of disease study to gather further information about the progression of Alport syndrome...
...CEO David Stadnyk says, "We have decided to make this move so our corporate structure is more in line with that of out peers. Having less shares outstanding trading at a proportionately higher price should also facilitate the raising of the additional funds needed to compete construction at our Southern Ontario project so we can meet the conditions of our pre-build license. That project is moving ahead on schedule and on budget."
...Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so" and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for...

More Content

All (59) | News (37) | Reports (0) | Blogs (20) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Regulus Announces Timing for Second Quarter 201... [Published 14 WFIE - 3 hours ago]
Regulus Announces Timing for Second Quarter 201... [Published PR Newswire: Health - 3 hours ago]
"Sorrento Therapeutics, Inc. - Mergers & Acquis... [Published SBWire - 9 hours ago]
Regulus Therapeutics Director Sells $11,135 in ... [Published American Banking News - Jul 26 2014]
Alnylam And Benitec [Published Seeking Alpha - Jul 25 2014]
Regulus Gains Orphan Drug Designation for micro... [Published Terrapinn - Jul 24 2014]
Regulus Receives FDA Orphan Status For Rare Kid... [Published Bioresearch Online - Jul 23 2014]
Regulus gets FDA orphan drug status for RG-012 ... [Published PBR - News - Jul 22 2014]
ACT Gets FDA Date, CGIX Opens Wallet, DPRX Once... [Published RTTNews.com - Jul 22 2014]
Sector Update: Health Care Stocks Mostly Lower;... [Published Nasdaq - Jul 21 2014]
Regulus Receives FDA Orphan Drug Designation fo... [Published PharmaceuticalProcessing - Jul 21 2014]
Regulus Gets Orphan Drug Designation For RG-012... [Published RTTNews.com - Jul 21 2014]
Regulus Therapeutics Inc receives orphan drug d... [Published Reuters - Jul 21 2014]
Regulus Therapeutics granted orphan drug design... [Published Yahoo! Finance - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published Wall Street Select - Jul 21 2014]
Regulus Therapeutics Director Isis Pharmaceutic... [Published American Banking News - Jul 21 2014]
Regulus Therapeutics Director Sells $34,000 in ... [Published American Banking News - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published ADVFN India - Jul 21 2014]
Regulus Receives Orphan Drug Designation for RG... [Published PR Newswire: Policy & Public Interest - Jul 21 2014]
Healthcare Review: Herbalife, Regulus Therapeut... [Published BioMedReports - Jul 18 2014]
Orphan Drug status for Regulus kidney disease t... [Published Seeking Alpha - Jul 18 2014]
Isis Pharmaceuticals Earns $1 Million from GSK ... [Published ADVFN UK - Jul 16 2014]
Regulus Therapeutics Director 1,750 Shares of ... [Published American Banking News - Jul 12 2014]
Movers and Shakers July 2014 [Published PM 360 - Jul 11 2014]
Comparative RNAseq in advanced heart failure [M... [Published PNAS - Jul 11 2014]
Commit To Purchase Regulus Therapeutics At $5, ... [Published Market Pulse Navigator - Jul 10 2014]
"Regulus Therapeutics Inc. - Product Pipeline R... [Published Good Day Sacramento - Jul 03 2014]
Alnylam Elects Amy Schulman to its Board of Dir... [Published Scottrade - Jul 02 2014]
Regulus Announces Patent Grant from U.S. Patent... [Published Scottrade - Jun 25 2014]
Regulus Announces Patent Grant from U.S. Patent... [Published PR Newswire: Policy & Public Interest - Jun 25 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Regulus Announces Timing for Second Quarter 201... [Published PR Newswire: Health - 3 hours ago]
LA JOLLA, Calif., July 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results ...
Regulus gets FDA orphan drug status for RG-012 ... [Published PBR - News - Jul 22 2014]
US-based biopharmaceutical firm Regulus Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for RG-012, a single stranded, chemically modified oligonucleotide. ...
Regulus Receives Orphan Drug Designation for RG... [Published PR Newswire: Policy & Public Interest - Jul 21 2014]
LA JOLLA, Calif., July 21, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration ...
Regulus Announces Patent Grant from U.S. Patent... [Published PR Newswire: Policy & Public Interest - Jun 25 2014]
LA JOLLA, Calif., June 25, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the U.S. Patent and Trademark ...
Regulus to Present at the Bank of America Merri... [Published PR Newswire: General Business - May 09 2014]
LA JOLLA, Calif., May 9, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific ...
1 2 3 4

Press Releases

sort by: Date | Relevance
Regulus Renews Strategic Alliance with Sanofi t... [Published Financial Services - Feb 05 2014]
Arcturus Therapeutics Appoints Zachary A. Zimme... [Published PR Newswire - Oct 28 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.